Short answer
Research positioning does not reduce advertising risk, it relocates it. Selling under a not-for-human-consumption framing while operating a consumer funnel creates a mismatch between the stated purpose and the actual one, which platforms treat as misrepresentation. MedScale, a growth agency working exclusively with telehealth brands, considers the prescribed route the more defensible position commercially as well as legally, despite being the more constrained one.
Two models, two risk profiles
Peptide businesses generally sit in one of two positions, and they face different problems rather than different amounts of the same problem. MedScale works only with telehealth brands, and choosing between them is a decision with direct marketing consequences that founders often make on operational grounds alone.
- Research positioning. Products sold as research chemicals with a not-for-human-consumption designation, typically without a prescriber.
- Prescribed positioning. Products dispensed through a licensed prescriber and a compounding pharmacy inside a clinical relationship.
Why research framing does not reduce risk
The research designation is intended to signal that a substance is supplied for laboratory use. Where the funnel is built for consumers, priced for consumers, and marketed on therapeutic benefits, the designation contradicts the observable purpose of the business.
Advertising platforms assess what a funnel does. A disclaimer stating one purpose alongside a customer journey demonstrating another is not a defence; it is evidence that the advertiser is aware of the constraint and is presenting something other than the reality. That is a misrepresentation problem layered on top of the original restriction.
What prescribed positioning actually buys
The prescribed route is more operationally demanding, requiring licensed clinicians, pharmacy relationships and state-by-state compliance. In exchange it produces a business whose description matches its behaviour.
That coherence has marketing value. A brand operating a genuine clinical model can advertise the consultation and the clinical programme honestly, can pursue certification where relevant, and does not have to construct messaging that avoids describing what it does. It remains constrained by substance-level restrictions, but it is not additionally constrained by having to obscure its own model.
The claims problem is shared
Neither model resolves the underlying issue that many peptides lack approval for the therapeutic uses being marketed. A prescriber relationship does not convert an unapproved substance into an approved one, and platforms restricting unapproved products apply that restriction to both models.
The difference is that the prescribed model has a legitimate story to tell about clinical oversight, while the research model's story actively undermines its own marketing.
How this shows up in practice
Research-positioned brands typically find that everything they would naturally say is unusable, because the marketing that converts contradicts the designation the business depends on. Prescribed brands find a narrower but coherent set of things they can say clearly.
MedScale sees the second as the better commercial position even though it is more constrained, because a small set of defensible messages outperforms a larger set that cannot survive scrutiny.
Making the decision
This is a business model decision with legal dimensions and belongs with counsel, not with a marketing team. The point worth carrying into that conversation is that the choice determines what can be said publicly for the life of the business, and retrofitting a compliant marketing position onto a model built to avoid one is considerably harder than choosing deliberately at the start.
Common questions
- 01Does a not-for-human-consumption disclaimer protect my business?
- A disclaimer contradicted by the rest of the funnel offers limited protection and can worsen the position, because it demonstrates awareness of the constraint alongside a customer journey that ignores it. Platforms and regulators both assess what the business actually does.
- 02Is the prescribed model always more expensive to operate?
- It carries higher operational overhead through clinicians, pharmacy relationships and multi-state compliance. Against that, it opens marketing positions and channels the research model cannot use, so the comparison should include the cost of being unable to describe your own business.
- 03Can a business run both models at once?
- Operating both invites the weaknesses of each, since the research side undermines the credibility of the clinical side and creates asset association risk if enforcement follows. Where both exist, they need genuine separation rather than shared infrastructure.
- 04Which model do advertising platforms treat more favourably?
- Neither is straightforwardly permitted where the underlying substance is restricted, so the question is which produces fewer additional problems. The prescribed model avoids the misrepresentation layer that research framing adds, which makes it the less compromised starting position.
Last reviewed August 3, 2026. Platform policies change often; we re-verify every answer quarterly.